PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy
NetScientific notes that portfolio company, PDS Biotechnology Corp., has announced positive preliminary data showing that its lead cancer immunotherapy treatment, PDS0101, has generated strong T-cell responses in pre-cervical cancer.
Currently, pre-cervical cancer is treated by surgical removal of lesions however; PDS0101 could offer an effective non-surgical alternative. Results show that it primes and activates the body’s defense mechanisms (T-cells) to recognize, target, and kill precancerous and cancerous cells that display HPV viral proteins, which are responsible for over 99% of cervical cancers. The patient population tested were those most likely to develop invasive cancer as they had little to no pre-treatment immune responses to HPV-16.
The results are the first demonstration of PDS Biotechnology’s proprietary synthetic immunotherapy technology, Versamune’s®, application in human cancer. They also mirror preclinical data which showed strong T-cell responses and aggressive tumor regression with low doses of the product. The results mark an important step towards the development of next generation therapies to treat early and late stage cancers and suggest that Versamune® could be used by other immuno-oncology platform technologies.
Other news from the department research and development
